Protocol Ledger

NCT04319367 · Phase II · RECRUITING

A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).

Interventional Phase II clinical trial protocol NCT04319367 sponsored by Imperial College London in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-17 Enrollment: 72 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04319367
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)72 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04319367
Protocol FieldVerified Registry Value
NCT IdentifierNCT04319367
Consolidated Lead SponsorImperial College London
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment72 participants (ESTIMATED)
Registered Start Date2021-05-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04319367
Hospital Research SiteLocationSite Profile
Aarhus University HospitalAarhus, DenmarkOpen Hospital Dossier ->
Western General HospitalEdinburgh, United KingdomOpen Hospital Dossier ->
Barts Health NHS TrustLondon, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI